| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.061 | 0.07 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.08 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.1 | 0.08 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.08 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.08 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.08 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.11 | 0.08 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.11 | 0.08 |